Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Deffered Revenue: 2015-2025

Historic Non-Current Deffered Revenue for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $54.2 million.

  • Editas Medicine's Non-Current Deffered Revenue changed negligibly% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $54.2 million for FY2024, which is 10.65% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Non-Current Deffered Revenue is $54.2 million, which was down 0.00% from $54.2 million recorded in Q2 2025.
  • Editas Medicine's 5-year Non-Current Deffered Revenue high stood at $68.9 million for Q2 2022, and its period low was $54.2 million during Q1 2024.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $54.2 million (2025), whereas its average is $56.6 million.
  • In the last 5 years, Editas Medicine's Non-Current Deffered Revenue plummeted by 60.10% in 2021 and then increased by 24.75% in 2022.
  • Over the past 5 years, Editas Medicine's Non-Current Deffered Revenue (Quarterly) stood at $60.9 million in 2021, then decreased by 0.36% to $60.7 million in 2022, then remained steady at $60.7 million in 2023, then decreased by 10.65% to $54.2 million in 2024, then remained steady at $54.2 million in 2025.
  • Its last three reported values are $54.2 million in Q3 2025, $54.2 million for Q2 2025, and $54.2 million during Q1 2025.